Trump announces nine new MFN drug pricing deals
Nine new companies have announced voluntary drug pricing deals with the White House, looking to avoid industry tariffs and inclusion in two CMS pilot programs under review that are thought to be potentially more financially ...
President Trump has announced nine new drug pricing deals with pharmaceutical companies. The companies - Alcon, Astellas, BeOne, BridgeBio, CSL, Sun Pharma, Kyowa Kirin, Teva, and UCB - have agreed to sell new medications to US patients at prices comparable to the lowest prices in peer countries. They will also offer their drugs to state Medicaid programs at "most-favored nation" prices.
According to STAT News, some companies may also bolster domestic manufacturing and contribute to US medical stockpiles. The deals are believed to help the companies avoid tariffs and inclusion in two CMS pilot programs. This round of agreements builds on 17 similar deals struck with larger drugmakers last year, including Pfizer, Eli Lilly, and Amgen.
The announcement is part of Trump's efforts to make healthcare more affordable, with a focus on lowering prescription drug costs. US patients currently pay some of the highest prices for prescription medicines in the world, often nearly three times more than in other developed nations.
Brief written by urgent.news from Endpoints News, STAT News, The Hill, Investing.com — 4 reports on this story. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
